Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

Author： Orditura Michele   Galizia Gennaro   Napolitano Vincenzo   Martinelli Erika   Pacelli Roberto   Lieto Eva   Aurilio Gaetano   Vecchione Loredana   Morgillo Floriana   Catalano Giuseppe   Ciardiello Fortunato   Genio Alberto Del   Martino Natale Di   De Vita Ferdinando  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.28, Iss.8, 2010-09, pp. : 820-827

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

ABSTRACTWe evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1–6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

Related content

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer

By Solomon B.   Ball D.L.   Richardson G.   Smith J.G.   Millward M.   MacManus M.   Michael M.   Wirth A.   O'Kane C.   Muceniekas L.   Ryan G.   Rischin D.  

Lung Cancer, Vol. 41, Iss. 3, 2003-09 ,pp. : 353-361 (9)

Elsevier

Access to resources Recommend Favorite

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

By Kim Jong   Sohn Sang   Song Hong   Kwon Ki-Young   Do Young   Lee Kyung   Hyun Myung   Ryoo Hun   Bae Sung   Park Keon   Baek Jin   Lee Won   Chung Joo   Cho Goon   Sohn Chang-Hak   Jang Jung   Chung Ho   Yu Wansik  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 6, 2007-11 ,pp. : 863-869 (7)

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401

By Takayama Koichi   Inoue Koji   Tokunaga Shoji   Matsumoto Takemasa   Oshima Tsukasa   Kawasaki Masayuki   Imanaga Tomotoshi   Kuba Mutsuo   Takeshita Masafumi   Harada Taishi   Shioyama Yoshiyuki   Nakanishi Yoichi  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1353-1359 (7)

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer

By Cappuzzo F.   De Marinis F.   Nelli F.   Calandri C.   Maestri A.   Benedetti G.   Migliorino M.R.   Cortesi E.   Rastelli F.   Martelli O.   Andruccetti M.   Bartolini S.   Crino L.  

Lung Cancer, Vol. 42, Iss. 3, 2003-12 ,pp. : 355-361 (7)

Elsevier

Access to resources Recommend Favorite

A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 99-100 (2)

Informa Healthcare

Access to resources Recommend Favorite